Amylyx Pharmaceuticals (AMLX) Other financing activities (2021 - 2023)

Amylyx Pharmaceuticals' Other financing activities history runs 3 years deep, the most recent figure standing at $347000.0 for Q4 2023.

• On a quarterly basis, Other financing activities fell 82.12% year-over-year to $347000.0 in Q4 2023; TTM through Dec 2023 was $7.0 million, a 219.51% increase from a year earlier, with the FY2023 full-year figure at $7.0 million, up 219.51% from the prior year.
• Other financing activities fell to $347000.0 in Q4 2023 per AMLX's latest filing, from $984000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $200.9 million in Q1 2022 and bottomed at -$200.6 million in Q2 2022.
• The 3-year median for Other financing activities is $347000.0 (2023), against an average of $866000.0.
• Biggest YoY gain for Other financing activities was 647954.84% in 2022; the steepest drop was 6688400.0% in 2022.
• Year by year, Other financing activities stood at $145000.0 in 2021, then soared by 1238.62% to $1.9 million in 2022, then tumbled by 82.12% to $347000.0 in 2023.
• Per Business Quant, the three latest AMLX Other financing activities figures stand at $347000.0 (Q4 2023), $984000.0 (Q3 2023), and $2.1 million (Q2 2023).